Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco

PLoS Medicine

Volumn 11, Issue 3, 2014, Pages

  Liu, Albert ^a,b   Cohen, Stephanie ^a,b   Follansbee, Stephen ^c   Cohan, Deborah ^b   Weber, Shannon ^b   Sachdev, Darpun ^a,b   Buchbinder, Susan ^a,b  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; TENOFOVIR;

ARTICLE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH MAINTENANCE ORGANIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MASS SCREENING; MEDICATION COMPLIANCE; POPULATION RISK; PREVALENCE; PROPHYLAXIS; RISK REDUCTION; SEROCONVERSION; SEXUAL TRANSMISSION; SOCIAL STIGMA; UNITED STATES;

ADENINE; ANTI-HIV AGENTS; DEOXYCYTIDINE; DISEASE MANAGEMENT; FEMALE; HIV INFECTIONS; HUMANS; MALE; ORGANOPHOSPHONATES; SAN FRANCISCO;

EID: 84898943192     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001613     Document Type: Article

References (58)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
2. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell, JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 367: 399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367: 423-434.
4. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, et al. (2013) Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381: 2083-2090.
5. Koenig LJ, Lyles C, Smith DK, (2013) Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies. Am J Prev Med 44: S91-98.
6. Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, et al. (2013) No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS ONE 8: e81997.
7. Liu AY, Vittinghoff E, Chillag K, Mayer K, Thompson M, et al. (2013) Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. J Acquir Immune Defic Syndr 64: 87-94.
8. Smith D, Grant R, Weidle P, Lansky A, Mermin J, et al. (2011) Interim guidance: preexposure prophylaxis for the prevention of HIV Infection in men who have sex with men. MMWR 60.
9. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, et al. (2013) The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med 10: e1001401.
10. Juusola JL, Brandeau ML, Owens DK, Bendavid E, (2012) The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 156: 541-550.
11. Schackman BR, Eggman AA, (2012) Cost-effectiveness of pre-exposure prophylaxis for HIV: a review. Curr Opin HIV AIDS 7: 587-592.
12. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure prophylaxis for HIV infection among African women. N Engl J Med 367: 411-422.
13. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, et al. (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). In: Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections; 3-6 March 2013; Atlanta, Georgia, United States of America. Abstract 26LB.
14. Arnold EA, Hazelton P, Lane T, Christopoulos KA, Galindo GR, et al. (2012) A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS ONE 7: e40603.
15. Saberi P, Gamarel KE, Neilands TB, Comfort M, Sheon N, et al. (2012) Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: a mixed methods study. PLoS ONE 7: e50061.
16. Fuchs JD, Sobieszczyk ME, Madenwald T, Grove D, Karuna ST, et al. (2013) Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants. J Acquir Immune Defic Syndr 63: 259-262.
17. Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, et al. (2012) Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS ONE 7: e33119.
18. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR, (2012) Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26: F13-19.
19. Hurt CB, Eron JJ Jr, Cohen MS, (2011) Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 53: 1265-1270.
20. Kurtz SP, Buttram ME, Surratt HL, (2013) Vulnerable infected populations and street markets for ARVs: potential implications for PrEP rollout in the USA. AIDS Care 26: 411-415.
21. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT, (2010) Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 54: 548-555.
22. Horberg M, Raymond B, (2013) Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance. Am J Prev Med 44: S125-128.
23. Myers JE, Sepkowitz KA, (2013) A pill for HIV prevention: deja vu all over again? Clin Infect Dis 56: 1604-1612.
24. De Man J, Colebunders R, Florence E, Laga M, Kenyon C, (2013) What is the place of pre-exposure prophylaxis in HIV prevention? AIDS Rev 15: 102-111.
25. Eakle R, Venter WD, Rees H, (2013) Pre-exposure prophylaxis for HIV prevention: ready for prime time in South Africa? S Afr Med J 103: 515-516.
26. Gupta RK, Van de Vijver DA, Manicklal S, Wainberg MA, (2013) Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. Retrovirology 10: 82.
27. Molina JM, Pintado C, Gatey C, Ponscarme D, Charbonneau P, et al. (2013) Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe? BMC Med 11: 186.
28. Rennie S, (2013) Ethical use of antiretroviral resources for HIV prevention in resource poor settings. Dev World Bioeth 13: 79-86.
29. Venter F, Allais L, Richter M, (2013) Exposure ethics: does Hiv pre-exposure prophylaxis raise ethical problems for the health care provider and policy maker? Bioethics In press.
30. Cohen MS, Muessig KE, Smith MK, Powers KA, Kashuba AD, (2012) Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS 26: 1585-1598.
31. World Health Organization (2012) Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Geneva: WHO.
32. Baeten JM, Haberer JE, Liu AY, Sista N, (2013) Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr 63 (Suppl 2) (): S122-129.
33. Center for Disease Control and Prevention (2010) Prevalence and awareness of HIV infection among men who have sex with men - 21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep 59: 1201-1207.
34. San Francisco Department of Public Health (2013) HIV/AIDS Epidemiology Annual Report 2012. San Francisco: HIV Epidemiology Section.
35. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD, (2010) Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr 53: 537-543.
36. Katz MH, Brigham TM, (2011) Transforming a traditional safety net into a coordinated care system: lessons from healthy San Francisco. Health Aff (Millwood) 30: 237-245.
37. Weber S, Waldura JF, Cohan D, (2013) Safer conception options for HIV serodifferent couples in the United States: the experience of the National Perinatal HIV Hotline and Clinicians' Network. J Acquir Immune Defic Syndr 63: e140-141.
38. Cohen SE, Liu AY, Bernstein KT, Philip S, (2013) Preparing for HIV pre-exposure prophylaxis: lessons learned from post-exposure prophylaxis. Am J Prev Med 44: S80-85.
39. Liu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, et al. (2008) Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 47: 241-247.
40. Campbell JD, Herbst JH, Koppenhaver RT, Smith DK, (2013) Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV. Am J Prev Med 44: S63-69.
41. Al-Tayyib AA, Thrun MW, Haukoos JS, Walls NE, (2013) Knowledge of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men in Denver, Colorado. AIDS Behav In press.
42. My PrEP Experience Blogspot. Available: http://myprepexperience.blogspot.com/p/truvada-track.html. Accessed 26 September 2013.
43. Truvada for PrEP Medication Assistance Program. Available: http://gilead.com/responsibility/us-patient-access/truvada%20for%20prep%20medication%20assistance%20program. Accessed 25 June 2013.
44. Krakower D, Mayer KH, (2012) Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Curr Opin HIV AIDS 7: 593-599.
45. Bernstein KT, Liu KL, Begier EM, Koblin B, Karpati A, et al. (2008) Same-sex attraction disclosure to health care providers among New York City men who have sex with men: implications for HIV testing approaches. Arch Intern Med 168: 1458-1464.
46. Mimiaga MJ, Goldhammer H, Belanoff C, Tetu AM, Mayer KH, (2007) Men who have sex with men: perceptions about sexual risk, HIV and sexually transmitted disease testing, and provider communication. Sex Transm Dis 34: 113-119.
47. Centers for Disease Control, Prevention (1994) HIV prevention practices of primary-care physicians-United States, 1992. MMWR Morb Mortal Wkly Rep 42: 988-992.
48. Loeb DF, Lee RS, Binswanger IA, Ellison MC, Aagaard EM, (2011) Patient, resident physician, and visit factors associated with documentation of sexual history in the outpatient setting. J Gen Intern Med 26: 887-893.
49. Montano DE, Phillips WR, Kasprzyk D, Greek A, (2008) STD/HIV prevention practices among primary care clinicians: risk assessment, prevention counseling, and testing. Sex Transm Dis 35: 154-166.
50. Norton WE, Larson RS, Dearing JW, (2013) Primary care and public health partnerships for implementing pre-exposure prophylaxis. Am J Prev Med 44: S77-79.
51. Hosek SG, (2013) HIV pre-exposure prophylaxis diffusion and implementation issues in nonclinical settings. Am J Prev Med 44: S129-132.
52. Bruno C, Saberi P, (2012) Pharmacists as providers of HIV pre-exposure prophylaxis. Int J Clin Pharm 34: 803-806.
53. Bayer R, Fairchild AL, (2006) Changing the paradigm for HIV testing-the end of exceptionalism. N Engl J Med 355: 647-649.
54. Smith R, Zetola NM, Klausner JD, (2007) Beyond the end of exceptionalism: integrating HIV testing into routine medical care and HIV prevention. Expert Rev Anti Infect Ther 5: 581-589.
55. Celum C, Baeten JM, Hughes JP, Barnabas R, Liu A, et al. (2013) Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations. J Acquir Immune Defic Syndr 63 (Suppl 2) (): S213-220.
56. Smith DK, Pals SL, Herbst JH, Shinde S, Carey JW, (2012) Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr 60: 421-427.
57. Mahajan AP, Sayles JN, Patel VA, Remien RH, Sawires SR, et al. (2008) Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS 22 (Suppl 2) (): S67-79.
58. Smit PJ, Brady M, Carter M, Fernandes R, Lamore L, et al. (2012) HIV-related stigma within communities of gay men: a literature review. AIDS Care 24: 405-412.